CellChorus — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

CellChorus is a private, early-stage biotech company founded in 2019 that has developed a unique AI-powered platform for dynamic single-cell functional analysis. Its core technology, TIMING™, visualizes and quantifies the behavior of thousands of individual cells in parallel, providing insights into cell therapy potency, antibody function, and immune response that are missed by conventional bulk or static single-cell methods. The company operates primarily as a technology platform and services provider, supporting pharmaceutical and biotech clients in preclinical research, candidate selection, and manufacturing consistency. CellChorus is positioned to address critical bottlenecks in immunotherapy development by delivering high-content, single-cell kinetic data.

OncologyInfectious Disease

Technology Platform

TIMING™ (Time-lapse Imaging Microscopy in Nanowell Grids) platform that uses visual AI (neural networks) to segment, track, and analyze the dynamic behavior (migration, interaction, killing, secretion) of thousands of individual cells over time. It enables correlation of functional kinetics with molecular profiling via retrieval of cells of interest.

Opportunities

The rapid growth of the cell therapy market creates a pressing need for predictive, high-content potency assays, which CellChorus is uniquely positioned to provide.

Expansion into new application areas beyond oncology, such as autoimmune diseases and infectious disease vaccine development, represents a significant growth vector.

The platform's ability to generate rich datasets also creates opportunities in AI-driven biomarker discovery and as a companion diagnostic tool.

Risk Factors

Primary risks include slower-than-expected adoption by pharmaceutical companies accustomed to conventional assays and competition from other high-content imaging and single-cell analysis companies.

As a private company, it also faces execution risks in scaling its technology and commercial operations, and depends on continued access to funding to support its growth.

Competitive Landscape

CellChorus competes with providers of bulk cell-based assays (e.g., Incucyte) and static single-cell analysis tools (e.g., 10x Genomics, standard flow cytometry). Its key differentiator is the integration of longitudinal, visual tracking of single-cell function with AI analytics and downstream molecular profiling. Niche competitors may include academic spin-offs and other AI-microscopy startups, but CellChorus's patented TIMING™ workflow and published validation in high-impact journals provide a competitive edge.

More companies in AI / Machine Learning →More companies in United States →